Navigation Links
Evidence-Based Medicine Debate Series Addresses Controversial Topics in the Diagnosis and Management of Alzheimer's Disease

PHOENIX, March 8, 2012 /PRNewswire/ -- Powered 4 Significance LLC, a Blue Ocean Pharma company, launched the first installment in its virtual EBM Debates™ series yesterday on the topic, "What is the role of neuroimaging in the diagnosis of Alzheimer's disease?" The series will include four debates over the course of the year focused on Alzheimer's disease, and will address other healthcare issues in future series. "We are extremely pleased to hold the inaugural event here in Phoenix with Dr. Marwan Sabbagh, MD, FAAN, and Director of the Banner Sun Health Research Institute in Sun City, Arizona, as our moderator," said Alden E. Masonis, PhD, co-founding partner of Powered 4 Significance and Blue Ocean Pharma. Dr. Sabbagh is also Founding Director Cleo Roberts Center for Clinical Research and Senior Scientist Haldeman Lab for Molecular Diagnostics and Therapeutics at Banner; Research Professor Department of Neurology University of Arizona College of Medicine, Phoenix; and, Steering Committee Member for the Alzheimer Disease Cooperative Study and Alzheimer's Disease Neuroimaging Initiative.

(Logo: )

The unique EBM Debates™ program has been developed based on an identified need for an open dialog among physicians involved in Alzheimer's disease research and disease management to understand what we know and what we must still document to make informed decisions. "The program will provide the opportunity to gain insights into what treating physicians think about the level of evidence available on these topics and provide a forum for open and honest commentary," said Dr. Sabbagh. "This will benefit all involved in the field of Alzheimer's by combining thought leader responses with feedback from the broad field of treating physicians."

The distinguished panel of debaters included: Dr. Liana Apostolova, Associate Professor in Neurology Mary S. Easton Center for Alzheimer's Disease Research and Director UCLA/Easton Neuroimaging Laboratory; Dr. James Brewer, Associate Professor in Radiology and Neurosciences University of California, San Diego; and Dr. Adam Fleisher, Director of Brain Imaging at Banner Alzheimer's Institute in Phoenix and Associate Professor of Neurosciences University of California, San Diego. Each provided valuable information on the direction and results of their research and lessons to be learned from their findings related to neuroimaging.

Virtual participants were able to register for the event and send in questions before and during the debate. In addition, polling questions were posted, which gave participants another tool to actively take part in the Alzheimer's discussion. The aim was to have the experts present their research and apply their observations and conclusions, to answer questions from the larger medical community involved with Alzheimer's.

The debate fostered an active exchange between the participants on the subject of using neuroimaging in the Alzheimer's diagnosis process and produced a significant number of audience questions. The debate will be archived and available for playback through the EBM Debates™ website ( Those interested in accessing this first debate or registering for future debates can reach out through the website. The next debate -- on the question, "Why are there so many late-stage drug development failures in Alzheimer's disease?" -- is scheduled for June 15, 2012.

Evidence-Based Medicine Debates (EBM Debates™)
The EBM Debates™ series has been created by Powered 4 Significance ( based on an identified need for an open dialog among physicians involved in disease research and management, for a better understanding of important and controversial issues in disease diagnosis and treatment. The goal is to bring together researchers, thought leaders, and treating physicians to gain insight into the evidence base and enable informed decision-making. For more information on the EBM Debates™, please visit

Blue Ocean Pharma LLC
Blue Ocean is on the forefront of developments in the pharmaceutical and healthcare sectors. Our services span the clinical development and commercialization needs of our clients and focus on supporting pharmaceutical, biotechnology, and device development, giving healthcare professionals the opportunity to optimize patient care and improve outcomes. The Blue Ocean Pharma Group of companies consists of Percolation Communications LLC, i.e. Strategy LLC, and Powered 4 Significance LLC. Together, the Group offers complementary and unique services that provide synergistic support addressing client needs. To learn more about Blue Ocean Pharma, please visit us at

Blue Ocean Pharma Contact:
Marco Winkler
+1 917 376 3019

SOURCE Blue Ocean Pharma LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Newly-Published Colchicine Safety Data Provide First Evidence-Based Dosing Guidance to Avoid Potentially Serious Interactions With Commonly Prescribed Drugs
2. Elsevier CPM Resource Center to Integrate Evidence-Based Clinical Content Software at Providence Health & Services
3. ScienceBased Health and Hoya Surgical Optics, Inc. Combine Forces to Expand Reach of Evidence-Based Nutraceuticals in Ophthalmic Market and Enhance Patient Care
4. CVS Caremark Announces Agreement With ActiveHealth Management for Evidence-Based Clinical Decision Support
5. Wolters Kluwer Health and the Joanna Briggs Institute Enter Exclusive Relationship to Deliver Evidence-Based Clinical Resources
6. B. Braun Customers Gain Premier Access to Zynx Health Device Networks Evidence-based, Customizable Drug Library Program
7. Increase in Cancer Imaging Illustrates Need for Evidence-Based Care
8. Evidence-Based Protocols in Cancer Treatment Reduce Variation, Improve Efficacy and Safety of Care
9. Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update
10. New Research Shows: Neurofeedback is an Evidence-Based Treatment for ADHD
11. Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicines 28th Annual Meeting
Post Your Comments:
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):